Literature DB >> 12079296

Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer?

Chin-Hsiung Hsieh1, Chan-Chao ChangChien, Hao Lin, Eng-Yen Huang, Chao-Cheng Huang, Kuo-Chung Lan, Shiuh-Young Chang.   

Abstract

OBJECTIVE: The aim of the present study was to evaluate whether a preoperative serum level of CA 125 in patients with endometrial cancer can provide additional information in determining the extent of lymphadenectomy required in the surgical staging and which cutoff value is optimal in this respect.
METHODS: CA 125 was measured in 124 patients diagnosed with endometrial carcinoma who underwent surgery at our institution between January 1995 and May 2000. Statistic analysis was performed using the Mann-Whitney U test and Kruskal-Wallis test to evaluate the association of preoperative CA 125 levels with various factors. The chi(2)/Fisher's exact test and a logistic regression model were employed to examine the effects of clinicopathological factors on serum CA 125 levels. Furthermore, a receiver operating characteristic curve was used to determine which cutoff value of the preoperative CA 125 was the optimal one.
RESULTS: Univariate analyses showed that elevated CA 125 levels were significantly correlated with an advanced stage, larger tumor size, increasing depth of the myometrial invasion, cervical invasion, positive cytology, and lymph node metastases (P < 0.05). Multivariate analyses using a logistic regression model showed lymph node metastases had the most significant effect on the elevation of CA 125 levels. The ROC curve determined that the best cutoff value was 40 U/ml; the sensitivity and specificity for screening lymph node metastases were found to be 77.8 and 81.0%, respectively.
CONCLUSION: Our data provide evidence indicating that a preoperative CA 125 level greater than 40 U/ml can be considered a criterion for full pelvic lymphadenectomy in the surgical staging of endometrial cancer. c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079296     DOI: 10.1006/gyno.2002.6664

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  34 in total

1.  Serum CA 125 levels and lymph node metastasis in patients with endometrial cancer.

Authors:  Iztok Takac; Borut Gorisek
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

2.  Metabolomic prediction of endometrial cancer.

Authors:  Ray O Bahado-Singh; Amit Lugade; Jayson Field; Zaid Al-Wahab; BeomSoo Han; Rupasri Mandal; Trent C Bjorndahl; Onur Turkoglu; Stewart F Graham; David Wishart; Kunle Odunsi
Journal:  Metabolomics       Date:  2017-12-01       Impact factor: 4.290

3.  Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Casper Reijnen; Joanna IntHout; Leon F A G Massuger; Fleur Strobbe; Heidi V N Küsters-Vandevelde; Ingfrid S Haldorsen; Marc P L M Snijders; Johanna M A Pijnenborg
Journal:  Oncologist       Date:  2019-06-11

4.  Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.

Authors:  Eleftheria Kalogera; Nathalie Scholler; Cecelia Powless; Amy Weaver; Ronny Drapkin; Jinping Li; Shi-Wen Jiang; Karl Podratz; Nicole Urban; Sean C Dowdy
Journal:  Gynecol Oncol       Date:  2011-10-28       Impact factor: 5.482

5.  Rural-urban differences in surgical treatment, regional lymph node examination, and survival in endometrial cancer patients.

Authors:  Whitney E Zahnd; Katherine S Hyon; Paula Diaz-Sylvester; Sonya R Izadi; Graham A Colditz; Laurent Brard
Journal:  Cancer Causes Control       Date:  2017-12-27       Impact factor: 2.506

6.  The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial.

Authors:  V Seebacher; S Polterauer; C Grimm; H Husslein; H Leipold; K Hefler-Frischmuth; C Tempfer; A Reinthaller; L Hefler
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

7.  Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Authors:  Richard G Moore; Amy K Brown; M Craig Miller; Donna Badgwell; Zhen Lu; W Jeffrey Allard; C O Granai; Robert C Bast; Karen Lu
Journal:  Gynecol Oncol       Date:  2008-05-21       Impact factor: 5.482

Review 8.  HE4 as a biomarker for ovarian and endometrial cancer management.

Authors:  Jinping Li; Sean Dowdy; Tracy Tipton; Karl Podratz; Wei-Guo Lu; Xing Xie; Shi-Wen Jiang
Journal:  Expert Rev Mol Diagn       Date:  2009-09       Impact factor: 5.225

9.  Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

Authors:  Zoya Yurkovetsky; Shlomo Ta'asan; Steve Skates; Alex Rand; Aleksey Lomakin; Faina Linkov; Adele Marrangoni; Lyudmila Velikokhatnaya; Matthew Winans; Elieser Gorelik; G Larry Maxwell; Karen Lu; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2007-07-19       Impact factor: 5.482

10.  The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.

Authors:  Roberto Angioli; Francesco Plotti; Stella Capriglione; Roberto Montera; Patrizio Damiani; Roberto Ricciardi; Alessia Aloisi; Daniela Luvero; Ester Valentina Cafà; Nella Dugo; Michela Angelucci; Pierluigi Benedetti-Panici
Journal:  Tumour Biol       Date:  2012-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.